生脉散通过上调1型11β-羟基类固醇脱氢酶对HepG2细胞胰岛素抵抗的改善作用
|
摘要
目的观察生脉散对HepG2细胞胰岛素抵抗及1型11β-羟基类固醇脱氢酶(11β-HSD1)的影响。方法建立胰岛素抵抗HepG2细胞模型,分别用MTT、葡萄糖氧化酶、RT-PCR、Western blotting检测生脉散对HepG2细胞增殖、葡萄糖消耗及11β-HSD1表达的影响。结果生脉散对HepG2细胞增殖及葡萄糖代谢无显著影响(P>0.05)。生脉散增加胰岛素抵抗HepG2细胞内葡萄糖含量、降低糖原含量,上调11β-HSD1表达(P<0.01或0.05)。结论生脉散可改善HepG2细胞胰岛素抵抗,其机制可能与上调11β-HSD1表达有关。
Objective To observe the effect of Shengmai powder(SMP) on insulin resistance and 11β-hydroxysteroid dehydrogenase type 1(11β-HSD1 in HepG2 cells.)Methods After insulin resistant HepG2 cells were established, the effect of SMP on proliferation, glucose metabolism, and 11β-HSD1 expression in HepG2 cells was determined by MTT, glucose oxidase, RT-PCR, and Western blotting, respectively. Results SMP had no effect on proliferation and glucose metabolism in HepG2 cells(P>0.05). However, SMP increased glucose but decreased glycogen contents, and upregulated 11β-HSD1 expression in insulin resistant HepG2 cells(P<0.01 or 0.05). Conclusion SMP could improve the insulin resistance in HepG2 cells through upregulation of 11β-HSD1 expression.
Objective To observe the effect of Shengmai powder(SMP) on insulin resistance and 11β-hydroxysteroid dehydrogenase type 1(11β-HSD1 in HepG2 cells.)Methods After insulin resistant HepG2 cells were established, the effect of SMP on proliferation, glucose metabolism, and 11β-HSD1 expression in HepG2 cells was determined by MTT, glucose oxidase, RT-PCR, and Western blotting, respectively. Results SMP had no effect on proliferation and glucose metabolism in HepG2 cells(P>0.05). However, SMP increased glucose but decreased glycogen contents, and upregulated 11β-HSD1 expression in insulin resistant HepG2 cells(P<0.01 or 0.05). Conclusion SMP could improve the insulin resistance in HepG2 cells through upregulation of 11β-HSD1 expression.
引文
[1]汪会琴,胡如英,武海滨,等.2型糖尿病报告发病率研究进展[J].浙江预防医学,2016,28(1):37-39,57.
[2]陈镇涛,王苓.吡格列酮联合二甲双胍对2型糖尿病患者胰岛素抵抗及炎性因子的影响[J].广东医科大学学报,2018,36(2):138-140.
[3]Chen W J,Fu Y,Yin X H,et al.Circulating levels of cortistatin are correlated with metabolic parameters in patients with newly diagnosed type 2 diabetes mellitus[J].Peptides,2017,94(2):86-90.
[4]Wu C H,Qiu S H,Zhu X Y,et al.Vitamin D supplementation and glycemic control in type 2 diabetes patients:Asystematic review and meta-analysis[J].Metabolism,2017,73(4):67-76.
[5]邓荞.生脉散加味治疗气阴两虚型糖尿病97例[J].光明中医,2014,29(5):977-978.
[6]邢晓伟,陈稚,郑博丹,等.生脉散对糖尿病大鼠胰岛素抵抗的改善作用[J].上海中医药杂志,2018,52(7):80-84.
[7]王景学,宋建新.生脉散治疗胰岛素抵抗的临床观察[J].光明中医,2007(1):60-61.
[8]王萍,王洋.生脉散在糖尿病治疗中的应用[J].天津中医药大学学报,2011,30(2):127-128.
[9]夏恒,马建春,陈吉生.生脉散及其各味中药治疗糖尿病研究进展[J].药学进展,2013,23(10):696-698.
[10]梁绍满,邓小敏.四逆散对2型糖尿病大鼠血糖、11β-HSD1及GR的影响[J].光明中医,2016,31(19):2799-2803.
[11]王兴友,陈杭薇,钱桂生,等.地塞米松对血管内皮细胞11β-HSD1基因表达的影响[J].解放军医学杂志,2007,32(10):1066-1068.
[12]张明.骨骼肌1型11β-羟基类固醇脱氢酶在2型糖尿病发病机制中的作用[D].吉林大学,2009.
[13]Masuzaki H,Paterson J,Shinyama H,et al.A transgenic model of visceralobesity and the metabolic syndrome[J].Science,2001,294(5549):2166-2170.
[14]Purnell J Q,Kahn S E,Samuels M H,et al.Enhanced cortisol production rates,free cortisol,and 11beta-HSD-1expression correlate with visceral fat and insulin resistance in men:effect of weight loss[J].Am J Physiol Endocrinol Metab,2009,296(2):E351-E357.
[15]Wake D J,Walker B R.Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity[J].Endocrine,2006,29(1):101-108.
[2]陈镇涛,王苓.吡格列酮联合二甲双胍对2型糖尿病患者胰岛素抵抗及炎性因子的影响[J].广东医科大学学报,2018,36(2):138-140.
[3]Chen W J,Fu Y,Yin X H,et al.Circulating levels of cortistatin are correlated with metabolic parameters in patients with newly diagnosed type 2 diabetes mellitus[J].Peptides,2017,94(2):86-90.
[4]Wu C H,Qiu S H,Zhu X Y,et al.Vitamin D supplementation and glycemic control in type 2 diabetes patients:Asystematic review and meta-analysis[J].Metabolism,2017,73(4):67-76.
[5]邓荞.生脉散加味治疗气阴两虚型糖尿病97例[J].光明中医,2014,29(5):977-978.
[6]邢晓伟,陈稚,郑博丹,等.生脉散对糖尿病大鼠胰岛素抵抗的改善作用[J].上海中医药杂志,2018,52(7):80-84.
[7]王景学,宋建新.生脉散治疗胰岛素抵抗的临床观察[J].光明中医,2007(1):60-61.
[8]王萍,王洋.生脉散在糖尿病治疗中的应用[J].天津中医药大学学报,2011,30(2):127-128.
[9]夏恒,马建春,陈吉生.生脉散及其各味中药治疗糖尿病研究进展[J].药学进展,2013,23(10):696-698.
[10]梁绍满,邓小敏.四逆散对2型糖尿病大鼠血糖、11β-HSD1及GR的影响[J].光明中医,2016,31(19):2799-2803.
[11]王兴友,陈杭薇,钱桂生,等.地塞米松对血管内皮细胞11β-HSD1基因表达的影响[J].解放军医学杂志,2007,32(10):1066-1068.
[12]张明.骨骼肌1型11β-羟基类固醇脱氢酶在2型糖尿病发病机制中的作用[D].吉林大学,2009.
[13]Masuzaki H,Paterson J,Shinyama H,et al.A transgenic model of visceralobesity and the metabolic syndrome[J].Science,2001,294(5549):2166-2170.
[14]Purnell J Q,Kahn S E,Samuels M H,et al.Enhanced cortisol production rates,free cortisol,and 11beta-HSD-1expression correlate with visceral fat and insulin resistance in men:effect of weight loss[J].Am J Physiol Endocrinol Metab,2009,296(2):E351-E357.
[15]Wake D J,Walker B R.Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity[J].Endocrine,2006,29(1):101-108.